270 related articles for article (PubMed ID: 22965939)
1. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.
Canu L; Pradella S; Rapizzi E; Fucci R; Valeri A; Briganti V; Giachè V; Parenti G; Ercolino T; Mannelli M
Arch Endocrinol Metab; 2017; 61(1):90-97. PubMed ID: 27737332
[TBL] [Abstract][Full Text] [Related]
3. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
[TBL] [Abstract][Full Text] [Related]
5. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
6. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
10. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
[TBL] [Abstract][Full Text] [Related]
12. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
Ayala-Ramirez M; Feng L; Habra MA; Rich T; Dickson PV; Perrier N; Phan A; Waguespack S; Patel S; Jimenez C
Cancer; 2012 Jun; 118(11):2804-12. PubMed ID: 22006217
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
[TBL] [Abstract][Full Text] [Related]
18. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
[TBL] [Abstract][Full Text] [Related]
20. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
